Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2021-04-06 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Reg 40(10) PCS certificate for the half year ended March 31, 2020
Regulatory Filings
2021-04-06 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It details the shareholding of a promoter and persons acting in concert as of March 31, 2021, including percentages of total shareholding and voting rights. The document is addressed to stock exchanges and is a formal notification of substantial acquisition of shares. This fits the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels crossing thresholds. The document is not a full financial report, earnings release, or management report, nor is it an announcement of a report publication. It is a regulatory disclosure specific to shareholding changes.
2021-04-05 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2021. It certifies the dematerialisation of securities and updating of records with depositories and stock exchanges. The document is short (2019 characters) and is a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is a regulatory filing related to securities and compliance with SEBI regulations, which fits best under the Regulatory Filings (RNS) category as a compliance certificate.
2021-04-05 English
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2021
Regulatory Filings
2021-04-05 English
Loss of Share Certificates
Regulatory Filings
2021-04-02 English
Details of Loss of Certificates
Regulatory Filings
2021-04-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.